Last reviewed · How we verify
Bumex (BUMETANIDE)
Bumex (BUMETANIDE) is a loop diuretic medication originally developed by a pharmaceutical company and currently owned by Validus Pharms. It targets the solute carrier family 12 member 1 and works by inhibiting sodium reabsorption in the kidneys, leading to increased urine production. Bumex is approved to treat various conditions, including edema, hepatic cirrhosis, and heart failure-related edema. The medication is off-patent and has multiple generic manufacturers. Key safety considerations include monitoring of electrolyte levels and potential side effects such as dehydration.
At a glance
| Generic name | BUMETANIDE |
|---|---|
| Sponsor | Validus Pharms |
| Drug class | Loop Diuretic [EPC] |
| Target | Solute carrier family 12 member 1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1983 |
Approved indications
- Edema
- Edema due to Hepatic Cirrhosis
- Peripheral Edema due to Chronic Heart Failure
- Pulmonary Edema due to Chronic Heart Failure
- Renal Disease with Edema
Boxed warnings
- WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dosage schedule have to be adjusted to the individual patient’s needs (see DOSAGE AND ADMINISTRATION ) .
Common side effects
- Hyperuricemia
- Hypochloremia
- Hypokalemia
- Azotemia
- Hyponatremia
- Increased serum creatinine
- Hyperglycemia
- Diuresis induced by bumetanide
- Muscle cramps
- Dizziness
- Hypotension
- Dehydration
Drug interactions
- fosinopril
- gentamicin
- kanamycin
- lithium
- netilmicin
- quinapril
- ramipril
- streptomycin
- tobramycin
Key clinical trials
- Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure (PHASE4)
- VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure (PHASE4)
- Bumetanide in Patients With Alzheimer's Disease (PHASE2)
- A Study of Ultra High Dose Diuretics to Treat Heart Failure (PHASE2)
- Pharmacokinetics of Drugs Administered to Children
- Diuretics and Volume Overload in Early CKD (PHASE4)
- Bumetanide vs. Furosemide in Cirrhosis (PHASE3)
- TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 12329731 | 2040-12-04 | Formulation |
| 11260038 | 2040-12-04 | Method of Use |
| 11123319 | 2040-12-04 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bumex CI brief — competitive landscape report
- Bumex updates RSS · CI watch RSS